logo/base Created with Sketch.
logo echosens
en-us
chevron Contact
English US version chevron
Change region

FibroScan® Mini+ 430

The mobile non-invasive solution for liver disease management, ideal for multi-site configuration.

Powered by LSM by VCTE™ and CAP™ for liver disease management.

Ideal point-of-care solution for large sized and community hospital-based settings.

chevron chevron
wave

FibroScan® Mini+ 430 is designed for multi-center sharing and remote liver patient management.

Awarded ergonomic design

LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement1. 3,800 peer-reviewed publications support the use of LSM by VCTE™.

CAP™ is unique patented and validated for liver disease management. 1,130 international peer-reviewed publications support the use of CAP™.

chevron Discover the clinical evidence

What our users say

quote

Assessment of liver stiffness and fat by non-invasive method is a huge step forward towards better management of MASLD. It has hugely impacted the way clinicians stratify the patients, chose therapy and monitor response!

Akash Shukla | Professor & Head Department of Gastroenterology Seth GSMC & KEM Hospital Mumbai

chevron Read all testimonials
chevron chevron

FibroScan® 430 Mini+ Indications for Use

The FibroScan® Mini+ 430 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE™) at 50 Hz shear
wave frequency and liver ultrasound attenuation coefficient (CAP™)* at 3.5 MHz. FibroScan liver stiffness measurements (LSM) by VCTE™ may
aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in
the assessment of liver fibrosis. FibroScan CAP™ measurements may be used, taken in context with other clinical and laboratory data, as an aid
in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population
should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP™ refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter). CAP™ on S+ probe is only available
with SmartExam capability.

 

References are available in our bibliography.

chevron Bibliography

Extend FibroScan® use

chevron Contact us